Neuromuscular complications of immune checkpoint inhibitor therapy

被引：43

作者：

Kolb, Noah A. ^{[1
]}

Trevino, Christopher R. ^{[2
]}

Waheed, Waqar ^{[1
]}

Sobhani, Fatemeh ^{[1
]}

Landry, Kara K. ^{[3
]}

Thomas, Alissa A. ^{[1
]}

Hehir, Mike ^{[1
]}

机构：

[1] Univ Vermont, Dept Neurol Sci, Burlington, VT 05405 USA

[2] MD Anderson, Dept Neurooncol, Houston, TX USA

[3] Univ Vermont, Med Ctr, Dept Med, 1 South Prospect St,MS 405AR2, Burlington, VT 05401 USA

来源：

MUSCLE & NERVE | 2018年 / 58卷 / 01期

关键词：

autoimmune drug reaction; cancer treatment; immune adverse events; immune checkpoint inhibitor; immunotherapy; neuromuscular; GUILLAIN-BARRE-SYNDROME; CELL LUNG-CANCER; INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY; NIVOLUMAB PLUS IPILIMUMAB; MYASTHENIA-GRAVIS; ADVERSE EVENTS; INTRAVENOUS IMMUNOGLOBULIN; ENTERIC NEUROPATHY; PRACTICE PARAMETER; CLINICAL-FEATURES;

D O I：

10.1002/mus.26070

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Immune checkpoint inhibitor (ICPI) therapy unleashes the body's natural immune system to fight cancer. ICPIs improve overall cancer survival, however, the unbridling of the immune system may induce a variety of immune-related adverse events. Neuromuscular immune complications are rare but they can be severe. Myasthenia gravis and inflammatory neuropathy are the most common neuromuscular adverse events but a variety of others including inflammatory myopathy are reported. The pathophysiologic mechanism of these autoimmune disorders may differ from that of non-ICPI-related immune diseases. Accordingly, while the optimal treatment for ICPI-related neuromuscular disorders generally follows a traditional paradigm, there are important novel considerations in selecting appropriate immunosuppressive therapy. This review presents 2 new cases, a summary of neuromuscular ICPI complications, and an approach to the diagnosis and treatment of these disorders. Muscle Nerve58: 10-22, 2018

引用

页码：10 / 22

页数：13

共 113 条

[1]

Abbas AK, 2015, BASIC IMMUNOLOGY, P1

[2]

Ahamadi M, 2017, CPT-PHARMACOMET SYST, V6, P49, DOI 10.1002/psp4.12139

[3] ACQUIRED INFLAMMATORY DEMYELINATING POLYNEUROPATHIES - CLINICAL AND ELECTRODIAGNOSTIC FEATURES [J].

ALBERS, JW ;

KELLY, JJ .

MUSCLE & NERVE, 1989, 12 (06) :435-451

[4] Drug-Associated Dermatomyositis Following Ipilimumab Therapy A Novel Immune-Mediated Adverse Event Associated With Cytotoxic T-Lymphocyte Antigen 4 Blockade [J].

Ali, Shirwa Sheik ;

Goddard, Allison L. ;

Luke, Jason J. ;

Donahue, Hilary ;

Todd, Derrick J. ;

Werchniak, Andrew ;

Vleugels, Ruth Ann .

JAMA DERMATOLOGY, 2015, 151 (02) :195-199

[5] CIDP diagnostic pitfalls and perception of treatment benefit [J].

Allen, Jeffrey A. ;

Lewis, Richard A. .

NEUROLOGY, 2015, 85 (06) :498-504

[6]

Alnahhas I, 2017, MUSCLE NERVE, V60, P210

[7]

Amin A, 2009, J CLIN ONCOL, V27

[8] Safety and antitumour activity of durvalumab plus tremelimumab in non-small-cell lung cancer: a multicentre, phase 1b study [J].

Antonia, Scott ;

Goldberg, Sarah B. ;

Balmanoukian, Ani ;

Chaft, Jamie E. ;

Sanborn, Rachel E. ;

Gupta, Ashok ;

Narwal, Rajesh ;

Steele, Keith ;

Gu, Yu ;

Karakunnel, Joyson J. ;

Rizvi, Naiyer A. .

LANCET ONCOLOGY, 2016, 17 (03) :299-308

[9] Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial [J].

Antonia, Scott J. ;

Lopez-Martin, Jose A. ;

Bendell, Johanna ;

Ott, Patrick A. ;

Taylor, Matthew ;

Eder, Joseph Paul ;

Jaeger, Dirk ;

Pietanza, M. Catherine ;

Le, Dung T. ;

de Braud, Filippo ;

Morse, Michael A. ;

Ascierto, Paolo A. ;

Horn, Leora ;

Amin, Asim ;

Pillai, Rathi N. ;

Evans, Jeffry ;

Chau, Ian ;

Bono, Petri ;

Atmaca, Akin ;

Sharma, Padmanee ;

Harbison, Christopher T. ;

Lin, Chen-Sheng ;

Christensen, Olaf ;

Calvo, Emiliano .

LANCET ONCOLOGY, 2016, 17 (07) :883-895

[10]

AstraZeneca, 2018, IMF DURV HIGH PRESCR

← 1 2 3 4 5 6 7 8 9 10 →